These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
212 related items for PubMed ID: 17229003
1. Biochemical assessment of Paget's disease of bone. Shankar S, Hosking DJ. J Bone Miner Res; 2006 Dec; 21 Suppl 2():P22-7. PubMed ID: 17229003 [Abstract] [Full Text] [Related]
2. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease. Garnero P, Gineyts E, Schaffer AV, Seaman J, Delmas PD. Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094 [Abstract] [Full Text] [Related]
3. Comparison of biochemical markers of bone turnover in Paget disease treated with pamidronate and a proposed model for the relationships between measurements of the different forms of pyridinoline cross-links. Randall AG, Kent GN, Garcia-Webb P, Bhagat CI, Pearce DJ, Gutteridge DH, Prince RL, Stewart G, Stuckey B, Will RK, Retallack RW, Price RI, Ward L. J Bone Miner Res; 1996 Aug; 11(8):1176-84. PubMed ID: 8854254 [Abstract] [Full Text] [Related]
4. Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone. Alexandersen P, Peris P, Guañabens N, Byrjalsen I, Alvarez L, Solberg H, Cloos PA. J Bone Miner Res; 2005 Apr; 20(4):588-95. PubMed ID: 15765177 [Abstract] [Full Text] [Related]
6. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease. Alvarez L, Guañabens N, Peris P, Monegal A, Bedini JL, Deulofeu R, Martinez de Osaba MJ, Muñoz-Gomez J, Rivera-Fillat F, Ballesta AM. J Bone Miner Res; 1995 Mar; 10(3):458-65. PubMed ID: 7785468 [Abstract] [Full Text] [Related]
7. Decreased beta-isomerization of the C-terminal telopeptide of type I collagen alpha 1 chain in Paget's disease of bone. Garnero P, Fledelius C, Gineyts E, Serre CM, Vignot E, Delmas PD. J Bone Miner Res; 1997 Sep; 12(9):1407-15. PubMed ID: 9286756 [Abstract] [Full Text] [Related]
8. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate. Hosking D, Lyles K, Brown JP, Fraser WD, Miller P, Curiel MD, Devogelaer JP, Hooper M, Su G, Zelenakas K, Pak J, Fashola T, Saidi Y, Eriksen EF, Reid IR. J Bone Miner Res; 2007 Jan; 22(1):142-8. PubMed ID: 17032148 [Abstract] [Full Text] [Related]
10. Monitoring of bone turnover biological, preanalytical and technical criteria in the assessment of biochemical markers. Withold W. Eur J Clin Chem Clin Biochem; 1996 Oct; 34(10):785-99. PubMed ID: 8933101 [Abstract] [Full Text] [Related]
12. Bone turnover markers in Paget's disease of the bone: A Systematic review and meta-analysis. Al Nofal AA, Altayar O, BenKhadra K, Qasim Agha OQ, Asi N, Nabhan M, Prokop LJ, Tebben P, Murad MH. Osteoporos Int; 2015 Jul; 26(7):1875-91. PubMed ID: 26037791 [Abstract] [Full Text] [Related]
13. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone. Walsh JP, Ward LC, Stewart GO, Will RK, Criddle RA, Prince RL, Stuckey BG, Dhaliwal SS, Bhagat CI, Retallack RW, Kent GN, Drury PJ, Vasikaran S, Gutteridge DH. Bone; 2004 Apr; 34(4):747-54. PubMed ID: 15050907 [Abstract] [Full Text] [Related]
18. Body mass index (BMI) and parameters of bone formation and resorption in postmenopausal women. Papakitsou EF, Margioris AN, Dretakis KE, Trovas G, Zoras U, Lyritis G, Dretakis EK, Stergiopoulos K. Maturitas; 2004 Mar 15; 47(3):185-93. PubMed ID: 15036488 [Abstract] [Full Text] [Related]